Abstract

The review of the problem of optimal antihypertensive therapy for patients with arterial hypertension (AH) with type 2 diabetes mellitus (T2DM) through the prism of the 2023 European Society of Hypertension Guidelines examines the issues of diagnosis, prevention and treatment of very high-risk patients. In the historical aspect, the evolution of knowledge regarding this problem is considered, data on the epidemiology of comorbid pathology are given, attention is focused on the target levels of blood pressure and approaches to its monitoring. The authors comment on important population studies with a high level of evidence in this regard, touch on the aspects of prescribing new classes of drugs, namely mineralocorticoid receptor agonists and sodium-dependent glucose cotransporter type 2 inhibitors for reducing blood pressure and glycemia, considering the classes and levels of evidence. At the end, the issue of prevention and treatment of manifestations of cardiovascular pathology in patients with type 2 diabetes is highlighted. Key words: arterial hypertension, type 2 diabetes, 2023 European Society of Hypertension Guidelines, diagnosis, prevention and treatment, cardiovascular pathology.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.